EryDex: Additional Phase II data

Additional data from an open-label, Italian Phase II trial in 22 patients with genetically-confirmed ataxia telangiectasia showed that monthly EryDex encapsulated in autologous erythrocytes reduced mean total ICAR score from baseline to 6 months, the primary endpoint, by 4 points (p=0.024). EryDex also improved the secondary endpoint of VABS total score from baseline to 6 months by 1.3 points (p<0.0001). Data were published in the Orphanet Journal of Rare Disease. EryDel previously reported that EryDex met the primary and secondary endpoints in the trial (see BioCentury, March 5, 2012). ...